Surgeries & Interventions

PCI Fizzles in REVIVED Study

PCI

The highly anticipated REVIVED trial found that percutaneous coronary intervention (PCI) does not reduce all-cause mortality or heart failure hospitalization in patients with severe ventricular dysfunction. 

The researchers thought that PCI would improve outcomes in these patients, all of whom had myocardial viability, extensive and stable coronary artery disease, and severe ischaemic left ventricular dysfunction (ejection fraction ≤ 35%). In fact, the researchers selected this patient population because they were the most likely cohort to experience PCI benefits. The authors wanted to “stack the deck” in favor of intervention. 

But when the investigators randomized 700 patients into either PCI or medical therapy groups, and then followed up between 2 and 8.5 years later, they found no clear PCI advantage.  

  • By a median of 3.4 years, 38% of the medical therapy group had either died or experienced heart failure hospitalization.
  • Surprisingly, the percentage was exactly the same in the PCI group (hazard ratio: 0.99).
  • There was also no difference in left ventricular ejection fraction at six and 12 months.
  • By 2 years, quality-of-life scores were not significantly different.

The Takeaway

The authors found no long-term benefit to the more invasive option for patients with stable coronary artery disease and impaired LV systolic function. That’s consistent with other studies showing PCI isn’t always safer or better than medication therapy for people with CAD, although it is the first to demonstrate these findings in this patient population. It might also prompt cardiologists to think twice before offering PCI to patients with ischemic cardiomyopathy.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Surgeries & Interventions June 23, 2025

Edwards’ Evoque Might Have More Adverse Events Than Previously Known June 23, 2025

Over a year after becoming the first FDA-approved transcatheter tricuspid valve replacement system, a new JACC study suggests Edwards Lifesciences’ Evoque TTVR system might have some risks that regulators hadn’t previously considered. Searching for more answers about Evoque’s real world risks, researchers pulled data from the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database […]

Cardiology Business June 19, 2025

Lilly Buys Verve, Bringing Gene Editing Mainstream June 19, 2025

Gene editing for heart disease just got a major boost as Eli Lilly acquired Verve Therapeutics and its one-dose cholesterol drugs for up to $1.3B, marking a new path for Verve’s therapies to go mainstream. Part of the acquisition likely stems from Verve’s recent impressive trial results for its PCSK9-blocking treatment, VERVE-102, which lowered LDL-C […]

Cardiac Imaging June 19, 2025

New AI-driven Tool Aids in Mitral Valve Assessment June 19, 2025

By: Jimmy Su, Ph.D. Principal Scientist, Cardiovascular Ultrasound, Philips A new tool, Automated 3D Color Flow Quantification (3D Auto CFQ), removes the reliance on assumptions when quantifying mitral regurgitation and replaces it with a reliable and robust, AI-driven method that delivers precise measurement of mitral valve regurgitant volume (RVol) regardless of orifice shape and size. Eliminating assumptions: Quantification […]

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!